Know Cancer

or
forgot password


Phase 3
18 Years
N/A
Open (Enrolling)
Both
Burkitt Lymphoma

Thank you

Trial Information


Inclusion Criteria:



- Age : 18 years or older

- Histologically or cytologically proven Burkitt lymphoma according to the WHO
classification

- WHO performance < 3

- Informed consent

Exclusion Criteria:

- Known HIV positive infection

- Positive serology for HCV and HBV (except after vaccination)

- Patients previously treated for lymphoma

- cardiac disease that contradict anthracycline chemotherapy

- Psychological or psychiatric condition who contradict steroids therapy

- Patients with serious renal failure unrelated to the lymphoma (serum creatinin level
higher than 150 mmole/L)

- Cirrhosis or severe hepatic failure unrelated to the lymphoma

- Previous malignant disease except basal cell skin carcinoma or in situ uterine cervix
carcinoma

- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule

- Primary organ transplant or other immunosuppressive conditions Pregnancy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Event free survival from date of first randomization

Principal Investigator

Vincent RIBRAG, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Gustave Roussy, Cancer Campus, Grand Paris

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

LMBA02

NCT ID:

NCT00180882

Start Date:

October 2004

Completion Date:

Related Keywords:

  • Burkitt Lymphoma
  • Burkitt Lymphoma
  • Lymphoma

Name

Location